More patients are seeking treatment for conditions that require immune globulin (Ig) therapy, but delays in diagnosis and treatment, as well as dissatisfaction with the quality of their care, remain a significant problem, according to a new survey from the Immunoglobulin National Society (IgNS).
The survey is the first of its kind, assessing patients’ infusion experience, safety, efficacy, access and outcomes across all diagnoses and routes of administration, and all sites